Replies to post #181000 on Biotech Values

[jbog]

Wow, at $1.29 a share he must have thought long and hard about this investment.

[DewDiligence]

ENTA—Today's announcement of the clinical advancement of EDP-239 (#msg-105063800) is probably the reason ENTA's CSO exercised options two days ago without selling the new shares. This is perfectly legal, of course.

[jbog]

ENTA’s CSO exercised and held shares worth $430K. The exercised options were not due to expire until 2016. This exercise-and-hold transaction occurred despite the fact that the CSO has a 10b5-1 plan.

After he spent $13k for the 11K shares he has now turned around and sold 5000 shares for $200K. Not a bad deal. A director did make a 1K market purchase but again I read nothing positive or negative about these trades.